Tango Therapeutics, Inc. (TNGX) Balance Sheet

The dramatic increase in total assets and equity in 2026Q2 reflects a substantial capital raise, likely from a public offering or private placement, which has bolstered the balance sheet. This infusion provides a multi-year cash runway, but the underlying business still shows escalating operating losses, suggesting the strengthened balance sheet is a temporary buffer rather than a sign of operational improvement. Investors should monitor how quickly this new capital is consumed given the widening quarterly burn.

The company's debt is modest and appears to be primarily lease-related or other non-material obligations, given the low D/E and stable debt levels. This suggests that the balance sheet is not burdened by significant interest-bearing liabilities, but the real leverage is operational, with fixed costs like R&D and SG&A driving cash burn. The low debt provides financial flexibility, but the lack of revenue growth means the company must rely on equity funding to sustain operations.

The absence of goodwill and the declining PPE net indicate that TNGX's value lies in its intellectual property and pipeline, not physical assets. The gradual depreciation of PPE suggests limited capital expenditure, consistent with a pre-commercial biotech. This asset mix implies that the balance sheet is not exposed to impairment risks from acquisitions, but the lack of tangible assets may limit collateral for future debt financing.

The equity surge is entirely attributable to new capital raised, not retained earnings, which continue to deteriorate as losses accumulate. The retained deficit of -$704.0M highlights the company's history of heavy investment in R&D without corresponding revenue. While the equity base is now substantial, the ongoing dilution from stock-based compensation and future capital raises may pressure existing shareholders, and the quality of equity is low given the reliance on external funding.

The current ratio is exceptionally high, indicating ample short-term liquidity to cover liabilities, but this is a result of the recent capital raise rather than operational efficiency. The cash position of $345.6M provides a runway of roughly 8-9 quarters at the current burn rate, but the burn is accelerating, as evidenced by the 66% increase in free cash flow burn over the past year. This suggests that while liquidity is currently strong, the company must achieve clinical milestones or additional funding before the cash is depleted.